Journal of Inherited Metabolic Disease

Article	Citations
Clinical and pathological characterization of ophthalmic disease in a canine model of mucopolysaccharidosis type I	56
Endocannabinoid receptor 2 is a potential biomarker and therapeutic target for the lysosomal storage disorders	49
New mouse models with hypomorphic SUMF1 variants mimic attenuated forms of multiple sulfatase deficiency	49
Uncommon case of mitochondrial disease: Mild amyotrophy of the legs and symmetrical lipomatosis of the arms	48
Long‐term cardiovascular outcomes and mortality with enzyme replacement therapy in patients with mucopolysaccharidosis type II	41
The clinical utility in hospital‐wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA‐related disorders	39
Isovaleric aciduria identified by newborn screening: Strategies to predict disease severity and stratify treatment	39
MOGS‐CDG: Quantitative analysis of the diagnostic Glc3Man tetrasaccharide and clinical spectrum of six new cases	38
Long‐term anthropometric development of individuals with inherited metabolic diseases identified by newborn screening	35
Metabolomics analysis of antiquitin deficiency in cultured human cells and plasma: Relevance to pyridoxine‐dependent epilepsy	32
Increased Survival in Patients With Molybdenum Cofactor Deficiency Type A Treated With Cyclic Pyranopterin Monophosphate	30
The impact of liver transplantation on health‐related quality of life in (acute) intoxication‐type inborn errors of metabolism	30
Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria	28
AAV‐mediated expression of galactose‐1‐phosphate uridyltransferase corrects defects of galactose metabolism in classic galactosemia patient fibroblasts	28
Towards values‐based healthcare for inherited metabolic disorders: An overview of current practices for persons with liver glycogen storage disease and fatty acid oxidation disorders	25
Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities	25
	25
Mucopolysaccharidoses type I gene therapy	22
Inborn errors of metabolism and their impact in paediatric dentistry	22
Long‐term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha‐mannosidosis: A phase 2, open label, multicenter study	22
Association between changes in pulmonary function and in patient reported outcomes during enzyme therapy of adult patients with late‐onset Pompe disease	22
Mild/moderate phenotypes in AADC deficiency: Focus on the aromatic amino acid decarboxylase protein	22
	22
Guidelines in the JIMD: Evidence‐based practice for inherited metabolic disease	22
Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin‐1‐deficient patients	20

Ornithine transcarbamylase deficiency: A diagnostic odyssey	20
Glutaminase 2 knockdown reduces hyperammonemia and associated lethality of urea cycle disorder mouse model	20
Altered neural oscillations in classical galactosaemia during sentence production	20
Tyrosine hydroxylase variants influence protein expression, cellular localization, stability, enzymatic activity and the physical interaction between tyrosine hydroxylase and GTP cyclohydrolase 1	19
The role of ERNDIM diagnostic proficiency schemes in improving the quality of diagnostic testing for inherited metabolic diseases	19
Propionic Acidemia‐Induced Proarrhythmic Electrophysiological Alterations in Human iPSC‐Derived Cardiomyocytes	17
Potential therapeutic uses of L‐citrulline beyond genetic urea cycle disorders	17
A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies	17
The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin‐deficient cells	17
Gene therapy for mitochondrial disorders	16
Brain morphometry in hepatic Wilson disease patients	16
Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value‐based healthcare approach and systematic benefit‐risk assessment	16
A 6‐month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications	16
Cognitive impairment in children and adults with cerebrotendinous xanthomatosis: A French cohort study	16
Phosphoinositide Metabolism: Biochemistry, Physiology and Genetic Disorders	16
Valine Restriction Extends Survival in a Drosophila Model of Short‐Chain Enoyl‐CoA Hydratase 1 (ECHS1) Deficiency	16
	16
Gene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia	15
Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1	15
The role of PGM1isoform 2 in PGM1‐CDG: One step closer to genotype–phenotype correlation?	15
Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism	15
Performance of Relative Exchangeable Copper for the Diagnosis of Wilson Disease in Acute Liver Failure	15
Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study	14
Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice	14
Multi‐omics in classical galactosemia: Evidence for the involvement of multiple metabolic pathways	14
A promoter variant in theOTCgene associated with late and variable age of onset hyperammonemia	14
Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective	14
Abnormal concentrations of acetylated amino acids in cerebrospinal fluid in acetyl‐CoA transporter deficiency	14
Cellular mechanisms of acute rhabdomyolysis in inherited metabolic diseases	14
A phenylalanine‐free recombinant nutritional protein for the dietary management of phenylketonuria	14
Physical training and high‐protein diet improved muscle strength, parent‐reported fatigue, and physical quality of life in children with Pompe disease	14
Issue Information	14
Subdural hematoma in glutaric aciduria type 1: High excreters are prone to incidental SDH despite newborn screening	14
Adherence to treatment, a challenge even in treatable metabolic rare diseases: A cross sectional study of Wilson's disease	14
On pathways and blind alleys—The importance of biomarkers in vitamin B6‐dependent epilepsies	13
Speech, Language and Non‐verbal Communication in CLN2 and CLN3 Batten Disease	13
Issue Information	13
Conserved quality control mechanisms of mitochondrial protein import	13
Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM mass spectrometry for screening of lysosomal storage disorders	13
	13
Phenotype and genotype of 197 British patients with McArdle disease: An observational single‐centre study	13
Impaired coenzyme A homeostasis in cardiac dysfunction and benefits of boosting coenzyme A production with vitamin B5 and its derivatives in the management of heart fa	12
Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment‐specific detoxification of glyoxylate	12
	12
Patents vs patients 1‐0: The case of chenodeoxycholic acid	12
Issue Information	12
Letter to the editor in response to Betzler et al.	12
Patient‐initiated conference focuses on bridging gaps between patients, clinicians and scientists in the field of rare neurotransmitter‐related disorders	12
Mitochondrial RNA processing defect caused by a SUPV3L1 mutation in two siblings with a novel neurodegenerative syndrome	12
NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model	12

Reversible white matter changes following a 4‐week high phenylalanine exposure in adults with phenylketonuria	12
Gene expression changes in Tay–Sachs disease begin early in fetal brain development	12
SSIEM 2022 Annual Symposium in Freiburg, Germany	12
Obituary for Charles Rider Roe, MD	12
	12
Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency	11
Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil	11
Corrigendum	11
Progression of Spinal Cord Disease in Adult Men With Adrenoleukodystrophy	11
State‐of‐the‐art 2023 on gene therapy for phenylketonuria	11
News from Valencia: JIMD themed issue on ureagenesis defects and allied disorders	11
Acute intermittent porphyria, givosiran, and homocysteine	11
	11
Inborn Errors of Cell Trafficking and Complex Lipids: A Further Step in Redefining Hereditary Metabolic Disorders	11
Postauthorization safety study of betaine anhydrous	11
Protein requirements in adults with phenylketonuria and bioavailability of glycomacropeptide compared to an l‐amino acid‐based product	11
Patterns of Penetrance and Expressivity of Long‐Term Outcomes in Classic Galactosemia	11
Gene therapy for glycogen storage diseases	11
Circulatory response to exercise relative to oxygen uptake assessed in the follow‐up of patients with fatty acid beta‐oxidation disorders	11
The potential and limitations of intrahepatic cholangiocyte organoids to study inborn errors of metabolism	11
Issue Information	11
High dose genistein in Sanfilippo syndrome: A randomised controlled trial	10
Influence of early identification and therapy on long‐term outcomes in early‐onset MTHFR deficiency	10
Global loss of bone, muscle, and fat mass in a patient with juvenile Paget disease (hereditary hyperphosphatasia)	10
Normothermic Machine Perfusion of Explanted Human Metabolic Livers: A Proof of Concept for Studying Inborn Errors of Metabolism	10
Neonatal presentation of occipital horn syndrome caused by a ATP7A missense variant	10
Experimental models of Barth syndrome	10
Eye movement disorders in inborn errors of metabolism: A quantitative analysis of 37 patients	10
	10
Addition of galactose‐1‐phosphate measurement enhances newborn screening for classical galactosemia	9
	9
Issue Information	9
Clinical presentation and natural history of Barth Syndrome: An overview	9
Issue Information	9
Impact of measuring heteroplasmy of a pathogenic mitochondrial DNA variant at the single‐cell level in individuals with mitochondrial disease	9
Phenotypic diversity, disease progression, and pathogenicity of MVK missense variants in mevalonic aciduria	9
Key terms and definitions in acute porphyrias: Results of an international Delphi consensus led by the European porphyria network	9
Neurotransmitters … it is all about communication!	9
Quantitative brain morphometry identifies cerebellar, cortical, and subcortical gray and white matter atrophy in late‐onset Tay‐Sachs disease	9
Severe neuromuscular forms of glycogen storage disease type IV: Histological, clinical, biochemical, and molecular findings in a large French case series	9
Neurologic outcome following liver transplantation for methylmalonic aciduria	9
Homocysteine metabolites inhibit autophagy, elevate amyloid beta, and induce neuropathy by impairing Phf8/H4K20me1‐dependent epigenetic regulation of mTOR in cystathionine β‐synt	9
Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy	8
A new D‐galactose treatment monitoring index for PGM1‐CDG	8
Levodopa‐refractory hyperprolactinemia and pituitary findings in inherited disorders of biogenic amine metabolism	8
Very long‐term outcomes in 23 patients with cblA type methylmalonic acidemia	8
An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin/cardiolipin ratio	8
A retrospective in‐depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management	8
The PompeQoL questionnaire: Development and validation of a new measure for children and adolescents with Pompe disease	8
Maternal and fetal outcomes in acute hepatic porphyria: A Swedish National Cohort Study	8
Adult‐onset diagnosis of urea cycle disorders: Results of a French cohort of 71 patients	8
Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships	8
Development of a novel tool for individual treatment trials in mucopolysaccharidosis	8
Abstracts	8
Beyond neuropsychological tests: AI speech analysis in PKU	8
Navigating the rare neurotransmitter disease diagnosis: Insights from patients and health care professionals	8
Pathological variants in nuclear genes causing mitochondrial complex III deficiency: An update	8
Outcomes after newborn screening for propionic and methylmalonic acidemia and homocystinurias	7
Review of the book “Vademecum Metabolicum, fifth edition”	7
Mitochondrial membrane synthesis, remodelling and cellular trafficking	7
The Metabolic Treatabolome and Inborn Errors of Metabolism Knowledgebase therapy tool: Do not miss the opportunity to treat!	7
Integration of multi‐omics layers empowers precision diagnosis through unveiling pathogenic mechanisms on maple syrup urine disease	7
Food or medicine? A European regulatory perspective on nutritional therapy products to treat inborn errors of metabolism	7
Issue Information	7
Biallelic missense variants in COG3 cause a congenital disorder of glycosylation with impairment of retrograde vesicular trafficking	7
Factors affecting activities of daily living among patients with Wilson disease	7
Response to Downie et al.	7
Altered lipid profile and reduced neuronal support in human induced pluripotent stem cell‐derived astrocytes from adrenoleukodystrophy patients	7
Benefits of using exchangeable copper and the ratio of exchangeable copper in a real‐world cohort of patients with Wilson disease	7
Cortical thickness and its relationship to cognitive performance and metabolic control in adults with phenylketonuria	7
Complex I, V, and MDH2 deficient human skin fibroblasts reveal distinct metabolic signatures by 1H HR‐MAS NMR	7
Targeted metabolomics revealed changes in phospholipids during the development of neuroinflammation in Abcd1tm1Kds mice and X‐linked adrenoleukodystrophy patients	7
Positive Clinical, Neuropsychological, and Metabolic Impact of Liver Transplantation in Patients With Argininosuccinate Lyase Deficiency	7
The Therapeutic Future for Congenital Disorders of Glycosylation	7
Issue Information	6
Safety, efficacy, and timing of transplantation(s) in propionic and methylmalonic aciduria	6
Variants in the ethylmalonyl‐CoA decarboxylase (ECHDC1) gene: a novel player in ethylmalonic aciduria?	6
Synergistic use of glycomics and single‐molecule molecular inversion probes for identification of congenital disorders of glycosylation type‐1	6
Investigation of GALNS variants and genotype–phenotype correlations in a large cohort of patients with mucopolysaccharidosis type IVA	6
Cytosolic phosphoenolpyruvate carboxykinase deficiency: Expanding the clinical phenotype and novel laboratory findings	6

ATP7A‐related copper transport disorders: A systematic review and definition of the clinical subtypes	6
Impact of pregnancy planning and preconceptual dietary training on metabolic control and offspring's outcome in phenylketonuria	6
Issue Information	6
Identification and characterization of novel MPC1 gene variants causing mitochondrial pyruvate carrier deficiency	6
Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency (PMM2‐CDG)	6
What can pediatricians learn from adult inherited metabolic diseases?	6
	6
Cardiac involvement in Wilson disease: Review of the literature and description of three cases of sudden death	6
Correction to Maternal and fetal outcomes in acute hepatic porphyria: A Swedish National Cohort Study	6
	6
Genetic defects in peroxisome morphogenesis (Pex11β, dynamin‐like protein 1, and nucleoside diphosphate kinase 3) affect docosahexaenoic acid‐phospholipid metabolism	5
Epidemiology and economic burden of Wilson disease in France: A nationwide population‐based study	5
Inborn disorders of the malate aspartate shuttle	5
Risk and potential of ChatGPT in scientific publishing	5
Human Milk Feeding in Inherited Metabolic Disorders: A Systematic Review of Growth, Metabolic Control, and Neurodevelopment Outcomes	5
N‐glycoproteomics reveals distinct glycosylation alterations in NGLY1‐deficient patient‐derived dermal fibroblasts	5
From skin lesions to tyrosinemia type II diagnosis	5
Insight on molecular pathogenesis and pharmacochaperoning potential in phosphomannomutase 2 deficiency, provided by novel human phosphomannomutase 2 structures	5
Role of Biomarkers in Diagnosing Disease, Assessing the Severity and Progression of Disease, and Evaluating the Efficacy of Therapies	5
Application of metabolite set enrichment analysis on untargeted metabolomics data prioritises relevant pathways and detects novel biomarkers for inherited metabolic disorders	5
EXPLORE B: A prospective, long‐term natural history study of patients with acute hepatic porphyria with chronic symptoms	5
Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning	5
Current Understanding of Pathogenic Mechanisms and Disease Models of Citrin Deficiency	5
Erratum	5
Abstracts	5
Gene therapy for aromatic L‐amino acid decarboxylase deficiency: Requirements for safe application and knowledge‐generating follow‐up	5
Clinical severity and cardiac phenotype in phosphomannomutase 2‐congenital disorders of glycosylation : Insights into genetics and management recommendations	5
Correction to “Comparative Analysis of Gene and Disease Selection in Genomic Newborn Screening Studies”	5
Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry	5
The complex machinery of human cobalamin metabolism	5
	5
Correction to “Clinical presentation of 13 children with alkaptonuria”	5
The management and clinical outcomes of pregnancies in women with urea cycle disorders: A review of the literature and results of an international survey	4
β‐Galactosidase therapy can mitigate blood galactose elevation after an oral lactose load in galactose mutarotase deficiency	4
Aldolase B Deficient Mice Are Characterized by Hepatic Nucleotide Sugar Abnormalities	4
Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: Consensus group recommendations from the German‐speaking countries	4
Clinical characteristics of primary carnitine deficiency: A structured review using a case‐by‐case approach	4
Thermo‐sensitive mitochondrial trifunctional protein deficiency presenting with episodic myopathy	4
Erratum	4
Obituary for Dr. Lawrence “Larry” Sweetman, PhD, ABMG (1942–2022)	4
Phenotypic prediction in glutaric aciduria type 1 combining in silico and in vitro modeling with real‐world data	4
The relation between dietary polysaccharide intake and urinary excretion of tetraglucoside	4
Genetic, biochemical, and clinical spectrum of patients with mitochondrial trifunctional protein deficiency identified after the introduction of newborn screening in the Netherlands	4
Human genetic defects of sphingolipid synthesis	4
A multinational study of acute and long‐term outcomes of Type 1 galactosemia patients who carry the S135L (c.404C > T) variant of GALT	4
Obituary for Claude Bachmann, MD (1941–2022)	4
Genetic aetiologies of acute liver failure	4
Disorders of fatty acid homeostasis	4
Mass cytometry reveals atypical immune profile notably impaired maturation of memory CD4 T with Gb3‐related CD27 expression in CD4 T cells in Fabry disease	4
Citrin deficiency—The East‐side story	4
Issue Information	4
Issue Information	4
	3
Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II	3
Role of liver transplantation in urea cycle disorders: Report from a nationwide study in Japan	3
In memoriam Willy Lehnert	3
Disorders of vesicular trafficking presenting with recurrent acute liver failure: NBAS, RINT1, and SCYL1 deficiency	3
Glycerophospholipids: Roles in Cell Trafficking and Associated Inborn Errors	3
Collaborative evaluation study on 18 candidate diseases for newborn screening in 1.77 million samples	3
Neuronopathic Gaucher disease: Rare in the West, common in the East	3
Issue Information	3
	3
Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment	3
Liver‐directed gene therapy for inherited metabolic diseases	3
Corrigendum	3
Gene therapies for mucopolysaccharidoses	3
Deficient glycan extension and endoplasmic reticulum stresses in ALG3‐CDG	3
Is the brain involved in patients with late‐onset Pompe disease?	3
Fructose‐1,6‐bisphosphatase deficiency causes fatty liver disease and requires long‐term hepatic follow‐up	3
Issue Information	3
	3
Quo vadis now: Beyond genomics to an era of personalised medicine	3
Neonatal GALT gene replacement offers metabolic and phenotypic correction through early adulthood in a rat model of classic galactosemia	3
Novel mRNA therapy restores GALT protein and enzyme activity in a zebrafish model of classic galactosemia	3
Clinical and biochemical distinctions for a metabolite repair disorder caused by NAXD or NAXE deficiency	3
Fatal cervical myelopathy in a child with glutaric aciduria type 1	3
Emergency Management of Intoxication‐Type Inherited Metabolic Disorders	3
New insights into the pathophysiology of methylmalonic acidemia	3
Gene therapy for urea cycle defects: An update from historical perspectives to future prospects	3
Aberrant autophagy in lysosomal storage disorders marked by a lysosomal SNARE protein shortage due to suppression of endocytosis	3
Identifying trajectories of fatigue in patients with primary mitochondrial disease due to the m.3243A > G variant	3
No effect of resveratrol in patients with mitochondrial myopathy: A cross‐over randomized controlled trial	2
Transmembrane helix 6 of ABCD4 is indispensable for cobalamin transport	2
Integrative omics approaches to advance rare disease diagnostics	2
Hepatic presentations of mitochondrial DNA depletion syndrome in children: A single tertiary liver centre experience	2
No effect of oral ketone ester supplementation on exercise capacity in patients with McArdle disease and healthy controls: A randomized placebo‐controlled cross‐over study	2
How longitudinal observational studies can guide screening strategy for rare diseases	2
Issue Information	2
Risk of postpartum hemorrhage in multiparous women with Gaucher disease: A call for reconsidering enzyme replacement therapy in all pregnant patients	2
Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies	2
Longitudinal volumetric analysis of gray matter atrophy in metachromatic leukodystrophy	2
Issue Information	2
ALG8‐CDG: Molecular and phenotypic expansion suggests clinical management guidelines	2
Excretion of excess nitrogen and increased survival by loss of SLC6A19 in a mouse model of ornithine transcarbamylase deficiency	2
Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran	2